Alkyne-substituted diminazene as G-quadruplex binders with anticancer activities

Eur J Med Chem. 2016 Aug 8:118:266-75. doi: 10.1016/j.ejmech.2016.04.030. Epub 2016 Apr 20.

Abstract

G-quadruplex ligands have been touted as potential anticancer agents, however, none of the reported G-quadruplex-interactive small molecules have gone past phase II clinical trials. Recently it was revealed that diminazene (berenil, DMZ) actually binds to G-quadruplexes 1000 times better than DNA duplexes, with dissociation constants approaching 1 nM. DMZ however does not have strong anticancer activities. In this paper, using a panel of biophysical tools, including NMR, FRET melting assay and FRET competition assay, we discovered that monoamidine analogues of DMZ bearing alkyne substitutes selectively bind to G-quadruplexes. The lead DMZ analogues were shown to be able to target c-MYC G-quadruplex both in vitro and in vivo. Alkyne DMZ analogues display respectable anticancer activities (single digit micromolar GI50) against ovarian (OVCAR-3), prostate (PC-3) and triple negative breast (MDA-MB-231) cancer cell lines and represent interesting new leads to develop anticancer agents.

Keywords: Anticancer therapeutics; G-quadruplex; Telomerase activity; Western blot; c-MyC.

MeSH terms

  • Alkynes / chemistry*
  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / metabolism*
  • Antineoplastic Agents / pharmacology*
  • Base Sequence
  • Cell Line, Tumor
  • Cell Survival / drug effects
  • Diminazene / chemistry
  • Diminazene / metabolism*
  • Diminazene / pharmacology*
  • G-Quadruplexes*
  • Humans
  • Proto-Oncogene Proteins c-myc / genetics
  • Proto-Oncogene Proteins c-myc / metabolism
  • Telomerase / antagonists & inhibitors

Substances

  • Alkynes
  • Antineoplastic Agents
  • Proto-Oncogene Proteins c-myc
  • Telomerase
  • Diminazene